In vitro and in vivo efficacy of tribendimidine and its metabolites alone and in combination against the hookworms Heligmosomoides bakeri and Ancylostoma ceylanicum.
Worldwide, 3 billion people are at risk of hookworm infection, particularly in resource-poor countries. While control of soil-transmitted helminthiases relies mostly on chemotherapy, only few drugs are available and concern about potential emergence of drug resistance is rising. In the present study, tribendimidine, a derivative of amidantel, and its metabolites deacylated amidantel (dADT) and acetylated deacylated amidantel (AdADT) were tested in vitro and in vivo against Heligmosomoides bakeri and Ancylostoma ceylanicum, two hookworm rodent models, alone or in combination with standard drugs. Tribendimidine achieved IC(50)s ≤ 5 μg/ml against both H. bakeri third-stage larvae and adults in vitro and a single 2 mg/kg oral dose resulted in complete worm elimination in vivo. Comparable results were obtained with dADT, whereas AdADT displayed no effect in vitro and gave a moderate worm burden reduction of 42.9% in H. bakeri-infected mice. Tribendimidine combined with albendazole, levamisole or ivermectin revealed antagonistic interactions against H. bakeri in vitro and no significant killing effect in vivo. Tribendimidine and dADT exerted high efficacies against A. ceylanicum third-stage larvae (IC(50)s < 0.5 μg/ml) whereas adults were moderately affected in vitro (IC(50)s > 88 μg/ml). In vivo at single oral doses of 10 mg/kg, dADT showed a slightly higher efficacy than tribendimidine, achieving worm burden reductions of 87.4% and 74.8%, respectively. At the same dose, AdADT reduced the worm burden by 57.9%. Synergistic interactions were observed with tribendimidine-levamisole combinations against A. ceylanicum in vitro (combination index at IC(50)=0.5), and in vivo (combination index at ED(90)=0.19). In conclusion, tribendimidine and dADT show potent anti-hookworm properties. The potential of the promising tribendimidine-levamisole combination should be investigated in greater detail.
Department of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Lucienne
L
Tritten
Uzoma
U
Nwosu
Mireille
M
Vargas
Jennifer
J
Keiser
D000284:Administration, Oral; D000722:Ancylostoma / Q000187:drug effects*; D000724:Ancylostomiasis / Q000188:drug therapy*; D000818:Animals; D000871:Anthelmintics / Q000008:administration & dosage* / Q000494:pharmacology; D006224:Cricetinae; D004195:Disease Models, Animal; D004357:Drug Synergism; D005260:Female; D020128:Inhibitory Concentration 50; D008297:Male; D008647:Mesocricetus; D051379:Mice; D010655:Phenylenediamines / Q000008:administration & dosage* / Q000494:pharmacology; D016896:Treatment Outcome; D014251:Trichostrongyloidea / Q000187:drug effects*; D014252:Trichostrongyloidiasis / Q000188:drug therapy*
D000871:Anthelmintics; D010655:Phenylenediamines; C056017:tribendimidine